A large validation study on the effect of single nucleotide polymorphisms on outcome and adverse events in sunitinib-treated patients with metastatic renal cell carcinoma (mRCC) only confirmed that ABCB1 and CYP3A5 variants are associated with progression-free survival and dose reductions, respectively. Does this mean 'game over' for polymorphism research in mRCC?
- Benoit Beuselinck
- Jessica Zucman-Rossi
